PharmaTimes - April 2019

Following months of heated debate in parliament and growing civil division, March 29 – the original date set for the UK’s separation from the European Union – looks set to pass amid yet more fighting and uncertainty, with MPs seemingly unable to agree the terms of the divorce and no one having a clear idea of what might happen next. As the Economist Intelligence Unit’s Ana Nicholls stresses (p20), the pharmaceutical industry and patients must be prepared for all eventualities, particularly with the looming threat of border delays and drug shortages.

Meanwhile, our cover feature this month (p16) considers the diverse needs of local NHS health economies as they respond to the NHS Long Term Plan. How can pharma best adapt to this new landscape and better engage with its customer?

On page 24, we find out what autonomous cars could teach digital healthcare about building engagement to help drive uptake. There’s also a look at the direction of digital health and some of the key collaborations that could impact patient care globally over the next year (p26), and the importance of a sound digital approach to achieving brand launch success (p34).

There’s also insight from Eric Hughes on his role at Novartis and the field of immuno-dermatology (p40), while Tracy Nesbit shares her experiences with insomnia on page 45. I hope you enjoy the issue!

April 2019 - magazine highlights

Patient Files: insomnia

Tracy Nesbit has experienced insomnia all her life. She te...

SmartPeople: Eric Hughes

We talk to Eric Hughes about his role as Novartis’ global...

The long arm of the law

Sheena Linehan takes a look at the recent legal cases impa...

Change mindset, change the future

How to orchestrate true value from customer engagement and...

In sickness and in health

In its finest hours, the bond between patients and pharma...

The pricing conundrum

Margaret Kyle takes a look at excessive pricing in the pha...

Transforming healthcare

Marcus Vass and Jane Whitcombe consider the future for dig...

The human factor

Richard McAleavy considers what autonomous cars can teach...

Gene therapy – high promise, high risk?

James Huang and Stephen Huang consider the promise and ris...

A state of confusion

The prospect of Brexit-related drugs shortages is looming,...

Where now for pharma?

Steve How and Paul Midgley, of Wilmington Healthcare, expl...